Arnav Kumar, MD
Interventional Cardiology · Warwick, RINPI 1114281672
Payments from drug & device makers
What this record shows
The money is spread across several categories — grants (48.6%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 38 manufacturers reported payments, led by Medtronic at 49.1% of the total. Reporting peaked in 2022 at $19,422 and has fallen 79.6% since, to $3,966 in 2025.
Across 279 payments — averaging $127.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$17K
- Abbott$7K
- Boston Scientific$2K
- Abiomed$1K
- Inari Medical, Inc.$923
- Edwards Lifesciences$849
- plus $6K from 32 others
What the payments were for
- Consulting fees$4001%
- Grants$17,25049%
- Travel & lodging$4,63413%
- Food & beverage$12,72836%
- Education$5021%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 33 | $17,434 |
| Abbott | 55 | $6,659 |
| Boston Scientific | 23 | $1,780 |
| Abiomed | 35 | $1,488 |
| Inari Medical, Inc. | 10 | $923 |
| Edwards Lifesciences | 14 | $849 |
| Cardiovascular Systems Inc. | 6 | $782 |
| Philips North America LLC | 2 | $697 |
| Acist Medical Systems, Inc. | 3 | $426 |
| Amgen | 11 | $418 |
| Teleflex LLC | 9 | $404 |
| Spectrawave, Inc | 1 | $400 |
| Baylis Medical Company Inc | 1 | $352 |
| Biotronik Inc. | 2 | $327 |
| Shockwave Medical, Inc | 3 | $315 |
| Heartflow, Inc. | 4 | $306 |
| Irhythm Technologies, Inc. | 12 | $209 |
| Penumbra, Inc. | 2 | $177 |
| Chiesi USA, Inc. | 3 | $174 |
| Novartis | 6 | $167 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $148 |
| E.r. Squibb & Sons, L.L.C. | 6 | $139 |
| Actelion Pharmaceuticals US, Inc. | 4 | $131 |
| Merck | 5 | $120 |
| Novo Nordisk | 2 | $115 |
| Sanofi-aventis U.S. LLC | 1 | $110 |
| Pfizer | 3 | $82 |
| Boehringer Ingelheim | 4 | $70 |
| W. L. Gore & Associates, Inc. | 2 | $55 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $52 |
| Lexicon Pharmaceuticals, Inc. | 2 | $47 |
| Kestra Medical Technology Services, Inc. | 1 | $36 |
| Smith+Nephew | 1 | $25 |
| AstraZeneca | 1 | $24 |
| Bayer | 1 | $21 |
| Johnson & Johnson | 1 | $19 |
| Cvrx, Inc. | 1 | $19 |
| Angiodynamics, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COREVALVE EVOLUT R$1,311
- AMPLATZER AMULET$1,001
- Watchman$938
- Diamondback Coronary$771
- FLOWTRIEVER CATHETER, S$759
- (9525) Intracardiac Und$674
- MitraClip$505
- CT THROMBECTOMY SYSTEM KIT$484
- HD-IVUS$426
- Impella$413
- HyperVue Imaging System$400
- NRG needle$352
- Orsiro Mission$327
- Edwards SAPIEN 3 Transcatheter Heart Valve$317
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$298
- Repatha$235
- GENERAL VASCULAR ACCESS$186
- TURNPIKE CATHETER$184
- FFRct$162
- ONYX FRONTIER$160
How this compares
$35,514 in reported general payments places this provider in the 85th percentile of 23 interventional cardiology providers in Rhode Island.
See all interventional cardiology providers in Rhode Island →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 25 | $25,540 |
| Torsemide | 22 | $407 |
| Metoprolol Succinate | 24 | $307 |
| ClopidogrelClopidogrel Bisulfate | 22 | $230 |
| Spironolactone | 20 | $196 |
| Rosuvastatin Calcium | 15 | $178 |
| Carvedilol | 15 | $82 |
| Hydrochlorothiazide | 13 | $66 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $82 | $25,54025 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 23 interventional cardiology providers in Rhode Island.
Other interventional cardiology in Warwick
- Mohammad Hashim MustehsanWarwick$29K
- Junyang LouWarwick$10K
- Murli RamanWarwick$569
- Peter SoukasProvidence$798K
- Jinnette AbbottProvidence$156K
- Marwan SaadProvidence$57K
- Walid SaberWoonsocket$29K
- Hafiz ImranProvidence$18K
- Paul GordonProvidence$13K
- Omar HyderProvidence$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.